CUREVAC NV (CVAC) Stock Fundamental Analysis
USA - NASDAQ:CVAC - NL0015436031 - Common Stock
5.37 USD
+0.01 (+0.19%)
Overall CVAC gets a fundamental rating of 6 out of 10. We evaluated CVAC against 534 industry peers in the Biotechnology industry. CVAC has an excellent financial health rating, but there are some minor concerns on its profitability. CVAC is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
CVAC had positive earnings in the past year.
CVAC had a positive operating cash flow in the past year.
In the past 5 years CVAC reported 4 times negative net income.
In multiple years CVAC reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 28.11%, CVAC belongs to the best of the industry, outperforming 98.13% of the companies in the same industry.
CVAC's Return On Equity of 33.02% is amongst the best of the industry. CVAC outperforms 97.75% of its industry peers.
With an excellent Return On Invested Capital value of 28.35%, CVAC belongs to the best of the industry, outperforming 98.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROIC | 28.35% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 37.93%, CVAC belongs to the top of the industry, outperforming 97.57% of the companies in the same industry.
CVAC has a better Operating Margin (40.58%) than 98.69% of its industry peers.
CVAC has a better Gross Margin (94.81%) than 94.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CVAC is creating value.
CVAC has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, CVAC has more shares outstanding
CVAC has a better debt/assets ratio than last year.
2.2 Solvency
CVAC has an Altman-Z score of 9.54. This indicates that CVAC is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 9.54, CVAC belongs to the best of the industry, outperforming 82.21% of the companies in the same industry.
CVAC has a debt to FCF ratio of 0.18. This is a very positive value and a sign of high solvency as it would only need 0.18 years to pay back of all of its debts.
CVAC has a Debt to FCF ratio of 0.18. This is amongst the best in the industry. CVAC outperforms 96.07% of its industry peers.
CVAC has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
CVAC has a Debt to Equity ratio of 0.05. This is in the lower half of the industry: CVAC underperforms 60.86% of its industry peers.
Although CVAC does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Altman-Z | 9.54 |
ROIC/WACC3.91
WACC7.25%
2.3 Liquidity
A Current Ratio of 6.17 indicates that CVAC has no problem at all paying its short term obligations.
The Current ratio of CVAC (6.17) is better than 64.42% of its industry peers.
A Quick Ratio of 6.16 indicates that CVAC has no problem at all paying its short term obligations.
The Quick ratio of CVAC (6.16) is better than 64.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 |
3. Growth
3.1 Past
CVAC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 170.16%, which is quite impressive.
The Revenue has grown by 675.15% in the past year. This is a very strong growth!
Measured over the past years, CVAC shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
3.2 Future
Based on estimates for the next years, CVAC will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
Based on estimates for the next years, CVAC will show a very negative growth in Revenue. The Revenue will decrease by -11.22% on average per year.
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
EPS Next 5Y-22.5%
Revenue Next Year-86.8%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.81%
Revenue Next 5Y-11.22%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 5.32, which indicates a rather cheap valuation of CVAC.
Compared to the rest of the industry, the Price/Earnings ratio of CVAC indicates a rather cheap valuation: CVAC is cheaper than 98.69% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.69. CVAC is valued rather cheaply when compared to this.
CVAC is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.32 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CVAC indicates a rather cheap valuation: CVAC is cheaper than 99.25% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, CVAC is valued cheaper than 99.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.29 | ||
| EV/EBITDA | 2.99 |
4.3 Compensation for Growth
CVAC has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as CVAC's earnings are expected to decrease with -31.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
5. Dividend
5.1 Amount
CVAC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CVAC (10/21/2025, 10:53:04 AM)
5.37
+0.01 (+0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.53%
Inst Owner Change-0.04%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.21B
Analysts72.31
Price Target4.92 (-8.38%)
Short Float %1.23%
Short Ratio2.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.18%
Min EPS beat(2)-39.67%
Max EPS beat(2)-18.68%
EPS beat(4)2
Avg EPS beat(4)34.62%
Min EPS beat(4)-39.67%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-1.81%
EPS beat(12)5
Avg EPS beat(12)-8.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.68%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)-86.88%
Revenue beat(4)2
Avg Revenue beat(4)75.38%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)53.09%
Revenue beat(12)4
Avg Revenue beat(12)21.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.59%
EPS NQ rev (1m)-275%
EPS NQ rev (3m)-275%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)220.62%
Revenue NQ rev (3m)220.62%
Revenue NY rev (1m)-14.11%
Revenue NY rev (3m)-14.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.32 | ||
| Fwd PE | N/A | ||
| P/S | 2.03 | ||
| P/FCF | 5.29 | ||
| P/OCF | 5.08 | ||
| P/B | 1.77 | ||
| P/tB | 1.85 | ||
| EV/EBITDA | 2.99 |
EPS(TTM)1.01
EY18.81%
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)1.02
FCFY18.91%
OCF(TTM)1.06
OCFY19.67%
SpS2.64
BVpS3.04
TBVpS2.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROCE | 33.37% | ||
| ROIC | 28.35% | ||
| ROICexc | 78.22% | ||
| ROICexgc | 88.03% | ||
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% | ||
| FCFM | 38.42% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 44.58% | ||
| Cap/Sales | 1.55% | ||
| Interest Coverage | 91.31 | ||
| Cash Conversion | 90.71% | ||
| Profit Quality | 101.3% | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | 9.54 |
F-Score9
WACC7.25%
ROIC/WACC3.91
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
Revenue Next Year-86.8%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.81%
Revenue Next 5Y-11.22%
EBIT growth 1Y171.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5Y10.78%
FCF growth 1Y160.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y182.06%
OCF growth 3YN/A
OCF growth 5YN/A